Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory study

Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory study

Bibliographic Details
Main Authors:	Jian Chu, Lillian Tung, Issam Atallah, Changli Wei, Melody Cobleigh, Ruta Rao, Steven B. Feinstein, Lydia Usha, Kathrin Banach, Jochen Reiser, Tochukwu M. Okwuosa
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	Cardio-Oncology
Online Access:	https://doi.org/10.1186/s40959-024-00205-5

Similar Items

Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study
by: Jian Chu, et al.
Published: (2024-01-01)

TISSUE PLASMINOGEN-ACTIVATOR VERSUS UROKINASE
by: Ebers, G
Published: (1988)

Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Induction by Etoposide in a Glioblastoma Cell Strain
by: Branko Brdar, et al.
Published: (2002-01-01)

The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
by: Spraggon, G, et al.
Published: (1995)

Serum Soluble Urokinase Plasminogen Activator Receptor Levels in Resistant Hypertension
by: Nergiz Bayrakcı, et al.
Published: (2024-04-01)

Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
by: Tetiana Yatsenko, et al.
Published: (2024-01-01)

Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.
by: Kapustin, A, et al.
Published: (2012)

Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
by: Tetiana Yatsenko, et al.
Published: (2024-03-01)

Urokinase-Type Plasminogen Activator System in Norm and in Life-Threatening Processes (Review)
by: Elena V. Kugaevskaya, et al.
Published: (2018-12-01)

The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
by: Ashna A. Kumar, et al.
Published: (2022-01-01)

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus
by: Ranadheer R. Dande, et al.
Published: (2017-01-01)

PLASMINOGEN ACTIVATING RECEPTOR UROKINASE (U-PAR): INTERACTION AND IMPLICATIONS IN TUMOR MICROENVIRONMENT IN LEUKEMIAS
by: JSV Campelo, et al.
Published: (2024-10-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

Involvement of Urokinase-Type Plasminogen Activator Receptor in the Formation of a Profibrotic Microenvironment in the Epicardial Region
by: K. V. Dergilev, et al.
Published: (2021-12-01)

Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells
by: Sherry Thornton, et al.
Published: (2017-03-01)

QSAR modelling to predict structural features of certain sulfonamide as Urokinase-type Plasminogen Activator inhibitors
by: Rahul D. Jawarkar, et al.
Published: (2024-06-01)

Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection
by: Sebastian M. Klim, et al.
Published: (2024-02-01)

Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
by: Auxtine Micalet, et al.
Published: (2023-12-01)

Doxorubicin-induced cardiotoxicity – Are plants the answer?
by: Pedro Mendes-Ferreira, et al.
Published: (2025-03-01)

Doxorubicin-induced cardiotoxicity and risk factors
by: Carl Belger, et al.
Published: (2024-02-01)

Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
by: Kjellman, A, et al.
Published: (2011)

Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
by: Gu, J, et al.
Published: (2005)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Koh, Angela S., et al.
Published: (2018)

Soluble urokinase plasminogen activator receptor: a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia
by: Muhammad Said El-Mekkawy, et al.
Published: (2022-02-01)

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk
by: Adithya K. Yadalam, MD, MSc, et al.
Published: (2025-01-01)

The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis
by: Fei Huang, et al.
Published: (2020-01-01)

The Role of Urokinase-Type Plasminogen Activator (UPA) Level and Some Biochemical Parameters in Iraqi Hemodialysis Patients
by: Fatima AL-Sudani, et al.
Published: (2024-07-01)

Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia
by: Rima S. Zahr, et al.
Published: (2024-05-01)

Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS
by: Sven H. Loosen, et al.
Published: (2024-05-01)

<i>N</i>-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer
by: Lisa Belfiore, et al.
Published: (2020-07-01)

The Urokinase-Type Plasminogen Activator Contributes to cAMP-Induced Steroidogenesis in MA-10 Leydig Cells
by: Zoheir B. Demmouche, et al.
Published: (2022-07-01)

The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin
by: Aleksey Michailovich Chaulin
Published: (2023-10-01)

Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice
by: Rui Fan, et al.
Published: (2023-08-01)

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

Febrile phase soluble urokinase plasminogen activator receptor and olfactomedin 4 as prognostic biomarkers for severe dengue in adults
by: Teo, Andrew, et al.
Published: (2024)

Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury
by: Wenwen Zhang, et al.
Published: (2024-12-01)

Diagnostic and prognostic value of lipopolysaccharide binding protein and soluble urokinase plasminogen activator receptor in dogs with parvoviral enteritis
by: Alparslan Burak Gucsav, et al.
Published: (2023-03-01)

Role of Urokinase-Type Plasminogen Activator Receptor in the Regulation of Angiogenic Properties of Sca1+ Vasculogenic Progenitor Cells
by: К. V. Dergilev, et al.
Published: (2022-04-01)

Estramustine Phosphate Inhibits TGF-β-Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production
by: Sonja S. Mojsilovic, et al.
Published: (2018-01-01)